Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Sell
44
SNOA Quote, Financials, Valuation and Earnings
Last price:
$3.53
Seasonality move
:
8.9%
Day range:
$3.19 - $3.61
52-week range:
$1.75 - $6.92
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.30x
P/B ratio:
1.42x
Volume:
12.4K
Avg. volume:
26.8K
1-year change:
32.71%
Market cap:
$5.4M
Revenue:
$14.3M
EPS (TTM):
-$2.19
Analysts' Opinion
-
Consensus RatingSonoma Pharmaceuticals, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 1 Buy rating, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $14.80, Sonoma Pharmaceuticals, Inc. has an estimated upside of 324.05% from its current price of $3.57.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $14.80 representing 100% downside risk from its current price of $3.57.
Fair Value
-
According to the consensus of 1 analyst, Sonoma Pharmaceuticals, Inc. has 324.05% upside to fair value with a price target of $14.80 per share.
SNOA vs. S&P 500
-
Over the past 5 trading days, Sonoma Pharmaceuticals, Inc. has underperformed the S&P 500 by -3.37% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Sonoma Pharmaceuticals, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Sonoma Pharmaceuticals, Inc. has grown year-over-year revenues for 5 quarters straight. In the most recent quarter Sonoma Pharmaceuticals, Inc. reported revenues of $5.6M.
Earnings Growth
-
Sonoma Pharmaceuticals, Inc. has grown year-over-year earnings for 9 quarters straight. In the most recent quarter Sonoma Pharmaceuticals, Inc. reported earnings per share of -$0.32.
Enterprise value:
2.9M
EV / Invested capital:
0.67x
Price / LTM sales:
0.30x
EV / EBIT:
--
EV / Revenue:
0.17x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-1.23x
Price / Operating cash flow:
23.61x
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$6.4M
Return On Assets:
-24.99%
Net Income Margin (TTM):
-20.54%
Return On Equity:
-77.39%
Return On Invested Capital:
-71.43%
Operating Margin:
-6.01%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $12.1M | $13.5M | $16.9M | $3.6M | $5.6M | |
| Gross Profit | $3.9M | $5.2M | $6.4M | $1.4M | $2.1M | |
| Operating Income | -$5.4M | -$4.3M | -$3.1M | -$850K | -$337K | |
| EBITDA | -$5.1M | -$4.1M | -$3M | -$815K | -$301K | |
| Diluted EPS | -$29.57 | -$4.89 | -$2.19 | -$0.59 | -$0.32 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $17.8M | $12.2M | $11.3M | $12M | $12.3M | |
| Total Assets | $19.8M | $15M | $13.6M | $13.7M | $13.9M | |
| Current Liabilities | $4.1M | $3.5M | $3.2M | $3.3M | $4.3M | |
| Total Liabilities | $8.4M | $7.9M | $8M | $8.3M | $10.1M | |
| Total Equity | $11.5M | $7M | $5.7M | $5.4M | $3.8M | |
| Total Debt | $1.5M | $492K | $134K | $46K | $391K | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$4.2M | -$1.5M | -$2.2M | $354K | -$635K | |
| Cash From Investing | -$67K | -$14K | -$165K | -$26K | -$10K | |
| Cash From Financing | $2.8M | $4M | $830K | $1.4M | -$62K | |
| Free Cash Flow | -$4.5M | -$1.5M | -$2.3M | $328K | -$645K | |
SNOA
Sector
Market Cap
$5.4M
$28.4M
Price % of 52-Week High
45.67%
50.35%
Dividend Yield
0%
0%
Shareholder Yield
-14.15%
-1.32%
1-Year Price Total Return
18.35%
-22.19%
Beta (5-Year)
1.638
0.521
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$3.27
200-day SMA
Buy
Level
$3.44
Bollinger Bands (100)
Sell
Level
3.3 - 4.5
Chaikin Money Flow
Sell
Level
-94.8M
20-day SMA
Buy
Level
$3.42
Relative Strength Index (RSI14)
Buy
Level
52.56
ADX Line
Buy
Level
21.88
Williams %R
Buy
Level
-96.8862
50-day SMA
Sell
Level
$3.75
MACD (12, 26)
Sell
Level
-0.14
25-day Aroon Oscillator
Sell
Level
-96
On Balance Volume
Neutral
Level
283M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-18.972)
Sell
CA Score
(Annual)
Level (-1.8474)
Buy
Beneish M-Score
(Annual)
Level (-4.0541)
Buy
Momentum Score
Level (8)
Sell
Ohlson Score
Level (3.9685)
Buy
Piotroski F Score
(Annual)
Level (6)
Buy
Quality Ratio Score
Level (8)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Sonoma Pharmaceuticals, Inc. is a global healthcare leader in the development and production of stabilized hypochlorous acid (HOCl) products. Its products are used for a wide range of applications, including wound care, eye care, nasal care, oral care, dermatological conditions, podiatry, animal health care, and non-toxic disinfectants. The company was founded by Hojabr Alimi and Linda Alimi in April 1999 and is headquartered in Boulder, CO.
Stock Forecast FAQ
In the current month, SNOA has received 1 Buy ratings 0 Hold ratings, and 0 Sell ratings. The SNOA average analyst price target in the past 3 months is $14.80.
-
Where Will Sonoma Pharmaceuticals, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Sonoma Pharmaceuticals, Inc. share price will rise to $14.80 per share over the next 12 months.
-
What Do Analysts Say About Sonoma Pharmaceuticals, Inc.?
Analysts are divided on their view about Sonoma Pharmaceuticals, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Sonoma Pharmaceuticals, Inc. is a Sell and believe this share price will drop from its current level to $14.80.
-
What Is Sonoma Pharmaceuticals, Inc.'s Price Target?
The price target for Sonoma Pharmaceuticals, Inc. over the next 1-year time period is forecast to be $14.80 according to 1 Wall Street analyst, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is SNOA A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Sonoma Pharmaceuticals, Inc. is a Buy. 1 of 1 analysts rates the stock a Buy at this time.
-
How Can I Buy Shares Of SNOA?
You can purchase shares of Sonoma Pharmaceuticals, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Sonoma Pharmaceuticals, Inc. shares.
-
What Is The Sonoma Pharmaceuticals, Inc. Share Price Today?
Sonoma Pharmaceuticals, Inc. was last trading at $3.53 per share. This represents the most recent stock quote for Sonoma Pharmaceuticals, Inc.. Yesterday, Sonoma Pharmaceuticals, Inc. closed at $3.57 per share.
-
How To Buy Sonoma Pharmaceuticals, Inc. Stock Online?
In order to purchase Sonoma Pharmaceuticals, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get SNOA Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
SNOA
Sector
P/E ratio
--
23.66x
PEG ratio
--
-0.01x
P/B ratio
1.42x
1.84x
Price / LTM sales
0.30x
1.60x
Growth Metrics
SNOA
Sector
Revenue growth
56.58%
4.85%
Earnings growth
45.01%
11.15%
Revenue (5-year growth)
-4.44%
6.45%
Earnings forecast
-$0.24
-$0.20
Profitability
SNOA
Sector
Profitability FY 2024
$5.5M
$3.6M
Return on invested capital
-71.43%
-30.98%
Return on assets
-24.99%
-27.62%
Return on equity
-77.39%
-36.69%
Earnings Date
Last Earnings Date
Aug
8
Next Earnings Date
Dec
5
Estimated Next Earnings Date
Mar
6
Balance Sheet
SNOA
Sector
Total cash
$3M
$27.2M
Short term investments
--
$25.7M
Total assets
$13.8M
$79.9M
Long term debt
$391K
$4.1M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Google Vs NVIDIA Stock: Which Is Best?
Alphabet (NASDAQ:GOOGL) and NVIDIA (NASDAQ:NVIDIA) are two of the market’s…
How High Could NVIDIA Stock Go?
NVIDIA (NASDAQ:NVDA) has been one of the best stocks to…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 62x
Buy
61
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 38x
Buy
63
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 40x
Alerts
Sell
44
PSTG alert for Dec 5
Pure Storage, Inc. [PSTG] is up 5.05% over the past day.
Sell
15
HOV alert for Dec 5
Hovnanian Enterprises, Inc. [HOV] is down 22.58% over the past day.
Buy
69
ASTS alert for Dec 5
AST Spacemobile, Inc. [ASTS] is up 18.25% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
